CardiologyOnline.net

Cardiology Xagena

Amiodarone ( Cordarone ) is an effective medication in preventing atrial fibrillation ( AF ), but it interferes with the metabolism of Warfarin ( Coumadin ). A study has examined the association of ...


Flecainide ( Almarytm, Tambocor ) is frequently used for treatment of cardiac arrhythmias in children. Due to concerns regarding increased mortality, there has been hesitancy to use Flecainide in chil ...


Provocative testing with sodium channel blockers is advocated for the evaluation of unexplained cardiac arrest ( UCA ) with the primary purpose of unmasking the typical ECG features of Brugada syndrom ...


Symptoms are a major driver for patients with atrial fibrillation to seek medical attention and are important to titrate atrial fibrillation therapies. However, a large proportion of patients with atr ...


Antiarrhythmic drugs ( AADs ) and anticoagulation are mainstays of atrial fibrillation ( AF ) treatment. A study has assessed the use and outcomes of antiarrhythmic therapy in anticoagulated patients ...


The results of the phase IV ATLANTIC study, which indicates that the profile of Ticagrelor ( Brilinta, Brilique ) is comparable whether administered in a pre-hospital or in-hospital setting to ST segm ...


American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes ( NSTE-ACS ). T ...


The vasodilator Cilostazol ( Pletal ), a phosphodiesterase-3 inhibitor, is approved in the United States for treatment of intermittent claudication. This study was aimed at evaluating its efficacy a ...


Women are more likely to develop anxiety and depression after a myocardial infarction than men, according to research presented at Acute Cardiovascular Care 2014, the annual meeting of the Acute Cardi ...


The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New ...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart ...


New data on investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction ( HFrEF ) have shown it has the potential to change the course of the disease for patients. ...


Eplerenone ( Inspra ) is the second MRA to be marketed in Canada after Spironolactone. Eplerenone has a Health Canada indication as an adjunct to standard therapy to reduce the risk of cardiovascular ...


Digoxin remains commonly used for rate control in atrial fibrillation, but very limited data exist supporting this practice and some studies have shown an association with adverse outcomes. Research ...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


The comparative safety of Dabigatran ( Pradaxa ) versus Warfarin ( Coumadin ) for treatment of non-valvular atrial fibrillation in general practice settings has not been established. Researchers fo ...


A study has assessed safety and cardiovascular outcomes of Dronedarone ( Multaq ) in patients with paroxysmal or persistent atrial fibrillation ( AF ) with coronary heart disease ( CHD ). Coronary h ...


At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...


Outcome data are limited on aortic valve replacement ( AVR ) in nonagenarian patients. This study reports the experience at Mayo Clinic ( Rochester, Minnesota, USA ) in the treatment of this elderly p ...


The myocardial effects of phosphodiesterase type 5 inhibitors ( PDE5i ) have recently received consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear. Resear ...


Results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial ( Apixaban after the initial Management ofPuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXT ...


The American Association for Thoracic Surgery ( AATS ) has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation ( POAF ) and f ...


In the ONTARGET ( Ongoing Telmisartan Alone and in Combination with Ramipril Trial ) trial, dual agent renin-angiotensin-aldosterone system ( RAAS ) blockade with angiotensin-converting-enzyme inhibit ...


Ventricular fibrillation is one of the most serious complications of acute myocardial infarction, with a high mortality rate. There is a lack of value of rescue thrombolysis in ST-segment elevation my ...


Despite endorsement of Digoxin in clinical practice guidelines, there exist limited data on its safety in atrial fibrillation / atrial flutter. The goal of a study was to evaluate the association o ...


Post-thrombotic syndrome ( PTS ) is a common and burdensome complication of deep venous thrombosis ( DVT ). Previous trials suggesting benefit of elastic compression stockings ( ECS ) to prevent post- ...


Body-mass index ( BMI ) and diabetes mellitus have increased worldwide, whereas global average blood pressure and cholesterol have decreased or remained unchanged in the past three decades. Research ...


The outcome of patients with ruptured abdominal aortic aneurysm ( rAAA ) varies by country. Study of practice differences might allow the formulation of pathways to improve care. Data from the Hosp ...


Four new oral anticoagulants compare favourably with Warfarin ( Coumadin ) for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups nee ...


LCZ696 has shown to be superior to Ace inhibitor Enalapril ( Enapren ) on key endpoints in the largest heart failure study ever done. In PARADIGM-HF patients with heart failure with reduced ejection f ...


Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. Serelaxin is a synthetic versi ...


Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan. The findin ...


Renal denervation ( RDN ) with radiofrequency ablation substantially reduces blood pressure in patients with treatment-resistant hypertension. Researchers have assessed the long-term antihypertensive ...


In final draft guidance NICE ( National Institute for Health and Care Excellence ) has defined which heart devices ( known as implantable cardiac devices ) are the most clinically and cost effective. ...


The use of non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic plaques would represent a major clinical advance for prevention and treatment of coronary artery disease. R ...


The aim of a study was to examine mortality and liver disease among patients exposed to Dronedarone ( Multaq ).There has been concern about the safety of Dronedarone, especially for patients with hear ...


It has been investigated whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. A large number of trials compared the diffe ...


Researchers have studied the effect of long term exposure to airborne pollutants on the incidence of acute coronary events in 11 cohorts participating in the European Study of Cohorts for Air Pollutio ...


The objective of a study was to assess whether a strategy of endovascular repair ( if aortic morphology is suitable, open repair if not ) versus open repair reduces early mortality for patients with s ...


Atrial fibrillation is the most common rhythm disorder seen in clinical practice. Antiarrhythmic drugs are effective for reduction of recurrence in patients with symptomatic paroxysmal atrial fibrilla ...


Studies have shown variation in the use of red blood cell transfusion among patients with acute coronary syndromes. There are no definitive data for the efficacy of transfusion in improving outcomes, ...


Left atrial fibrosis is prominent in patients with atrial fibrillation ( AF ). Extensive atrial tissue fibrosis identified by delayed enhancement magnetic resonance imaging ( MRI ) has been associated ...


A strategy using mechanical chest compressions might improve the poor outcome in out-of-hospital cardiac arrest, but such a strategy has not been tested in large clinical trials. The LINC study has ...


Coronary artery calcium ( CAC ), measured by computed tomography ( CT ), has strong predictive value for incident cardiovascular disease events. The standard CAC score is the Agatston, which is weight ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation ( AF ) trials, the drug was found to have divergent effects on ...


Metformin ( Glucophage ) treatment is associated with improved outcome after myocardial infarction in patients with diabetes mellitus. In animal experimental studies Metformin preserves left ventricul ...


Dronedarone ( Multaq ) is an Amiodarone analog that differs structurally from Amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added. These modifications reduce thyr ...


Hospital cooling improves outcome after cardiac arrest, but prehospital cooling immediately after return of spontaneous circulation may result in better outcomes. A randomized clinical trial was do ...


Secretory phospholipase A2 ( sPLA2 ) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2 inhibitor Varespladib has favorable effects on lipid and inflammatory markers; h ...


The role of nutrition in preventing peripheral artery disease ( PAD ) remains elusive. Mediterranean diets reduce the risk of myocardial infarction and stroke. They also may reduce the risk of PAD, bu ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati